+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Do prescription stimulants increase the risk of adverse cardiovascular events? A systematic review



Do prescription stimulants increase the risk of adverse cardiovascular events? A systematic review



BMC Cardiovascular Disorders 12(1): 41



There is increasing concern that prescription stimulants may be associated with adverse cardiovascular events such as stroke, myocardial infarction, and sudden death. Public health concerns are amplified by increasing use of prescription stimulants among adults. Methods The objective of this study was to conduct a systematic review of the evidence of an association between prescription stimulant use and adverse cardiovascular outcomes. PUBMED, MEDLINE, EMBASE and Google Scholar searches were conducted using key words related to these topics (MESH): ADHD; Adults; Amphetamine; Amphetamines; Arrhythmias, Cardiac; Cardiovascular Diseases; Cardiovascular System; Central Nervous Stimulants; Cerebrovascular; Cohort Studies; Case control Studies; Death; Death, Sudden, Cardiac; Dextroamphetamine; Drug Toxicity; Methamphetamine; Methylphenidate; Myocardial Infarction; Stimulant; Stroke; Safety. Eligible studies were population-based studies of children, adolescents, or adults using prescription stimulant use as the independent variable and a hard cardiovascular outcome as the dependent variable. Results Ten population-based observational studies which evaluated prescription stimulant use with cardiovascular outcomes were reviewed. Six out of seven studies in children and adolescents did not show an association between stimulant use and adverse cardiovascular outcomes. In contrast, two out of three studies in adults found an association. Conclusions Findings of an association between prescription stimulant use and adverse cardiovascular outcomes are mixed. Studies of children and adolescents suggest that statistical power is limited in available study populations, and the absolute risk of an event is low. More suggestive of a safety signal, studies of adults found an increased risk for transient ischemic attack and sudden death/ventricular arrhythmia. Interpretation was limited due to differences in population, cardiovascular outcome selection/ascertainment, and methodology. Accounting for confounding and selection biases in these studies is of particular concern. Future studies should address this and other methodological issues.

(PDF emailed within 1 workday: $29.90)

Accession: 036528006

Download citation: RISBibTeXText


Related references

Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review. Bmc Cardiovascular Disorders 12(): 41-41, 2012

Do prescription stimulants increase the risk ofadverse cardiovascular events? A systematic review. 2012

Fish oil administration in older adults with cardiovascular disease or cardiovascular risk factors: is there potential for adverse events? A systematic review of the literature. International Journal of Cardiology 168(4): 4371-4375, 2014

Autoimmune Diseases May Increase Adverse Cardiovascular Events After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Heart, Lung and Circulation 2018, 2018

Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. Cmaj 183(12): 1359-1366, 2011

Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 344: E2856, 2012

Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: A systematic review and meta-analysis of 13,395 patients. Diabetes and Vascular Disease Research 14(5): 400-406, 2017

Systematic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel. Alimentary Pharmacology and Therapeutics 48(8): 780-796, 2018

A Systematic Review on the Adverse Events of Prescription Opioids. Archives of Physical Medicine and Rehabilitation 95(10): E40-E41, 2014

Risk of stroke in prescription and other amphetamine-type stimulants use: A systematic review. Drug and Alcohol Review 37(1): 56-69, 2017

Anti-EGFR monoclonal Antibodies increase the risk of severe Gastrointestinal adverse events in Cancer Patients: a systematic review and meta-analysis. Clinical Therapeutics 37(8): E83-E84, 2015

Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta-Analysis of Prospective Studies. Journal of the American Heart Association 6(7), 2018

Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 300(12): 1439-1450, 2008

T1078 Risk of Adverse Cardiovascular Events With Concomitant use of Clopidogrel and Proton Pump Inhibitors(Ppi): Systematic Review and Meta-Analysis of Observational Studies. Gastroenterology 138(5): S-483, 2010

Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. British Journal of Dermatology 176(4): 890-901, 2016